title: Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases.
abstract: Aims and background. To report the clinical outcome of linac-based or robotic, image-guided stereotactic body radiotherapy in patients affected by abdominal lymph node metastases from different primary cancers. Methods and methods. Twenty-six patients with 32 abdominal lymph node metastases were consecutively treated at the University of Florence between April 2011 and May 2012. The mean follow-up was 4.6 months (SD, 3.9; range, 0.3-13). The dose prescription ranged between 24 Gy and 36 Gy delivered in 1-5 fractions. Results. In terms of local control, complete response to stereotactic body radiotherapy was obtained in 18 cases (66.7%), partial response in 7 (25.9%), and stable disease in 2 (7.4%). At the Cox univariate regression analysis, an increased risk of partial response or absence of local response to radiotherapy was found for subjects of the female sex (P = 0.036), age less than 50 years (P = 0.022), primary tumor of the genital tract (P = 0.007), and previous chemotherapy (P = 0.057). An excellent local control rate (90.9%) was obtained in patients affected by abdominal lymph node metastases of prostatic origin. Conclusions. Stereotactic body radiotherapy for abdominal lymph node metastases is a safe and effective treatment in terms of high rates of local control, especially in a subset of patients affected by prostate cancer.
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Bonomo
authors.forename: Samantha
authors.initials: S
authors.lastname: Cipressi
authors.forename: Calogero
authors.initials: C
authors.lastname: Saieva
authors.forename: Daniela
authors.initials: D
authors.lastname: Greto
authors.forename: Laura
authors.initials: L
authors.lastname: Masi
authors.forename: Fabiola
authors.initials: F
authors.lastname: Paiar
authors.forename: Vanessa
authors.initials: V
authors.lastname: Di Cataldo
authors.forename: Icro
authors.initials: I
authors.lastname: Meattini
authors.forename: Sara
authors.initials: S
authors.lastname: Cecchini
authors.forename: Monica
authors.initials: M
authors.lastname: Mangoni
authors.forename: Raffaela
authors.initials: R
authors.lastname: Doro
authors.forename: Carmine
authors.initials: C
authors.lastname: Iermano
authors.forename: Ivano
authors.initials: I
authors.lastname: Bonucci
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Livi
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Biti
mesh_terms: D000005:Abdomen; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000473:pathology; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000473:pathology / Q000528:radiation effects*; D008207:Lymphatic Metastasis / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000473:pathology; D016634:Radiosurgery; D012189:Retrospective Studies; D012307:Risk Factors; D012371:Robotics; D012737:Sex Factors; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000473:pathology